Skip to main content
Back
CRMD logo

CorMedix Inc.

Data quality: 100%
CRMD
NASDAQ Healthcare Biotechnology
$6.42
▲ $0.17 (2.72%)
Mkt Cap: 507.50M
Day Range
$6.28 $6.51
52-Week Range
$5.60 $17.43
Volume
1,384,671
50D / 200D Avg
$7.16 / $10.71
Prev Close
$6.25

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 3.1 0.4
P/B 1.3 2.9
ROE % 66.6 3.7
Net Margin % 52.3 3.8
Rev Growth 5Y % 535.7 10.0
D/E 0.4 0.2

Key Takeaways

Revenue grew 535.65% annually over 5 years — strong growth
ROE of 66.56% indicates high profitability
Net margin of 52.31% shows strong profitability
Debt/Equity of 0.37 — conservative balance sheet
Generating 172.79M in free cash flow
P/E of 3.11 — trading at a low valuation

Growth

Revenue Growth (5Y)
535.65%
Revenue (1Y)617.03%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
66.56%
ROIC20.32%
Net Margin52.31%
Op. Margin48.17%

Safety

Debt / Equity
0.37
Current Ratio2.01
Interest Coverage53.97

Valuation

P/E Ratio
3.11
P/B Ratio1.25
EV/EBITDA3.40
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 617.03% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 535.65% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 311.71M Net Income (TTM) 163.06M
ROE 66.56% ROA 19.74%
Gross Margin 88.46% Operating Margin 48.17%
Net Margin 52.31% Free Cash Flow (TTM) 172.79M
ROIC 20.32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.37 Current Ratio 2.01
Interest Coverage 53.97 Dividend Yield 0.00%
Valuation
P/E Ratio 3.11 P/B Ratio 1.25
P/S Ratio 1.63 PEG Ratio -0.01
EV/EBITDA 3.40 Dividend Yield 0.00%
Market Cap 507.50M Enterprise Value 510.59M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 311.71M 43.47M 0.0 65,408.0 190,936.0
Net Income 163.06M -17.93M -46.34M -29.70M -28.21M
EPS (Diluted) 2.04 -0.30 -0.91 -0.74 -0.75
Gross Profit 275.75M 40.28M -205,562.0 61,674.0 41,998.0
Operating Income 150.14M -22.36M -48.96M -30.62M -29.44M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 826.14M 118.85M 82.06M 62.04M 68.95M
Total Liabilities 420.84M 34.19M 11.92M 6.98M 6.15M
Shareholders' Equity 405.31M 84.66M 70.14M 55.06M 62.80M
Total Debt 148.91M 517,013.0 667,632.0 802,433.0 923,801.0
Cash & Equivalents 145.83M 40.65M 43.64M 43.37M 53.32M
Current Assets 350.47M 114.58M 79.45M 59.55M 66.47M
Current Liabilities 174.27M 33.84M 11.40M 6.31M 5.35M

Strategy Scores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#281 of 1024
56
Custom Capital Light Compounder
#4 of 213
83
Custom Contrarian Investing (David Dreman)
#36 of 658
76
Value Value Investing (Warren Buffett)
#23 of 195
55

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Capital Light Compounder
Mar 24, 2026
Entered Contrarian Investing (David Dreman)
Mar 24, 2026
Entered Value Investing (Warren Buffett)
Mar 24, 2026